DOCSLIB.ORG

RU-CINJ Cancer Connection Magazine • Fall 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RU-CINJ Cancer Connection Magazine • Fall 2014 Autumn I 201 4 It Takes TEAMW ORK: Non-Hodgkin’s lymphoma took Munson McLeod on a detour. A bone marrow transplant put him back on track. Director ’s Corne r As a National Cancer Institute “The great thing in this world is not so (NCI)-designated Comprehensive Cancer Center, Rutgers Cancer much where we stand, as in what direction Institute of New Jersey already has we are moving.” earned the respect of the global – Oliver Wendell Holmes, Sr. – American Writer cancer community for upholding the highest standards of conducting cancer research and delivering recipient and others leading up to our most recent 1,000th case, patient care. Reaching this level you will learn how this program – delivered in conjunction with of achievement carries with it a Robert Wood Johnson University Hospital – has evolved since its great responsibility – not simply to inception 20 years ago (page 6) . ‘maintain’ these standards but You will discover on page 20 how as a teen, Keith Pasichow’s to raise the bar to surpass them. life was changed by a diagnosis of bone cancer. Now an adult, As you’ll learn in this issue, a $ 10 this one-time theater major shifted his focus to become a pediatric million anonymous gift was made hematologist/oncologist, having been inspired by the care he to launch a Cancer Diagnostics and Therapeutics Program that will received at the Cancer Institute. be transformative for cancer research and patient care in New Jersey And while some transformations provide immediate effect, and beyond (page 12) . As a partnership between the Cancer others have a lasting impact. Such is the case with a gift from Institute of New Jersey, RUCDR Infinite Biologics ® within the Jewels of Charity that will support an innovative clinical trial initiative Human Genetics Institute of New Jersey and Rutgers Department at the Cancer Institute (page 25) – and a gift from Rutgers of Genetics, this program will use cutting-edge technology to University alums Bernice and Carl Venable will help further develop novel cancer treatments by identifying genomic abnormal - advance research opportunities (page 26) . ities in tumor tissue that can be targeted with specific drugs. Such While we continue to raise the bar in the delivery of patient care ‘personalized’ therapy is the aim of our precision medicine initiative and propelling next generation research, it is a mission we can and is expected to offer additional expertise and treatment options only accomplish as a collective. We hope you will continue to join for patients. This partnership brings research and technology di - us on this journey. rectly to patients by bridging two leading institutes within Rutgers Sincerely, University, attesting to success inherent in the integration of the Cancer Institute within Rutgers. Advancement of cancer research and its impact on patient care is illustrated through such programs as our Blood and Marrow Robert S. DiPaola, MD Transplant Program. In anecdotes from our very first transplant Director, Rutgers Cancer Institute of New Jersey David J. Foran, PhD Isaac Yi Kim, MD, PhD Roger Strair, MD, PhD Chief Informatics Officer and Chief, Urologic Oncology Chief, Hematologic Executive Director, Bioinformatics Malignancies/Hematopoietic Edmund C. Lattime, PhD Robert S. DiPaola, MD and Computational Imaging Stem Cell Transplantation Associate Director for Director Shridar Ganesan, MD, PhD Education and Training Antoinette M. Stroup, PhD David A. August, MD Associate Director for Director, New Jersey State Sharon Manne, PhD Chief, Surgical Oncology Translational Science Cancer Registry Associate Director for Joseph R. Bertino, MD Darlene Gibbon, MD Cancer Prevention, Control Linda Tanzer Chief Scientific Officer Chief, Gynecologic Oncology and Population Science Chief Administrative Officer and Associate Director for Kevin Coyle Susan Goodin, Pharm D Lorna Rodriguez, MD, PhD Administration and Planning Chief Financial Officer Executive Director, Director, Precision Medicine Statewide Affairs Deborah L. Toppmeyer, MD Richard Drachtman, MD Karen Shapiro, MBA, MPH Chief Medical Officer and Interim Chief, Pediatric Bruce G. Haffty, MD Director, Operations Chief, Solid Tumor Oncology Hematology/Oncology Chair, Radiation Oncology Eileen White, PhD Howard L. Kaufman, MD, FACS Associate Director for Associate Director for Clinical Basic Science Science and Chief Surgical Officer Autumn I 2014 6 In This Issue I Features: 6 It Takes Teamwork The Blood and Marrow Transplant Program at Rutgers Cancer Institute of New Jersey recently marked its 1,000 th procedure. We take a closer look at some of those patients – then and now. By Maryann Brinley 12 $10 Million Gift will Enhance Patient Care , R esearch and Education An anonymous $ 10 million gift is helping transform how cancer is targeted and treated. By Eve Jacobs 16 Knowledge is Power When three doctors from the Urologic Oncology Program collaborate on a case of prostate cancer, the patient can only win. By Maryann Brinley 12 20 Life Interrupted At 15, Keith Pasichow was enjoying summer camp and hanging out with friends. But unusual swelling in his thigh began a journey with cancer 16 that would later lead him to help youngsters on that same path. By Michele Fisher I Departments: 2 Forefront News from the front lines at Rutgers Cancer Institute of New Jersey. 25 Making a Difference News on how giving and service are making a difference in 20 the fight against cancer at Rutgers Cancer Institute of New Jersey. 28 Survivor’s Corner Life lessons on weathering the storm known as 'cancer.' 30 Network Spotlight News from our Network hospitals around the state. 32 Homefront A close up look at the lives of faculty and staff members at Rutgers Cancer Institute of New Jersey. Autumn 2 014 I Cancer Connection I 1 Forefront News from the front lines at Rutgers Cancer Institute of New Jersey Training the Next Generation N I Breast Surgery Fellowship C K The R O Program at Rutgers Cancer Institute of M A N e New Jersey and Rutgers Robert Wood N K O Johnson Medical School received a $75,000 training grant from the Breast Cancer Alliance to support a surgical fellow Even though melanoma “Because melanoma for academic year 2014-2015. It is the patients are at an increased risk of can be detected third consecutive year that the non-profit disease recurrence and the develop - on the skin, a visual, entity has given this award to the program. ment of a second, unrelated mela- web-based approach The one-year fellowship provides sur - noma, research from Rutgers Cancer geons who have completed their general Institute of New Jersey shows that to educating melanoma surgery residency with advanced training many patients do not perform a regu - survivors about and experience lar, thorough self-exam of their skin or disease surveillance that pre pares sufficiently engage in sun protection strategies is ideal.” them to provide behaviors. To address these concerns, — Elliot J. Coups, PhD comprehensive Cancer Institute of New Jersey behav - care specifically ioral scientist Elliot J. Coups, PhD for patients with (above) , will develop and test a web- feature information on how to do breast disease. based behavioral intervention for this regular skin self-exams as well as re - Through the pro - group. minders about sun-safe behaviors. gram, they learn “Because melanoma can be detect- Interactive tasks and quizzes will also how to apply a ed on the skin, a visual, web-based be included. multidisciplinary approach to educating melanoma More than 400 melanoma survivors approach to the survivors about disease surveillance will test the 12-month intervention. prevention, diagnosis and treatment of strategies is ideal,” notes Dr. Coups, The information gained will help refine breast cancer and rehabilitation of breast who is also an associate professor of the tool for a larger-scale evaluation cancer patients. medicine at Rutgers Robert Wood trial. A $2.5 million grant (R01CA Fellows also participate in clinical and/or Johnson Medical School. 171666) from the National Cancer laboratory research at the Cancer Institute The intervention will be designed to Institute will support the work. I with opportunities to design and imple - have the look and feel of an “app” that ment clinical trials. They also train in might be used on a tablet or smart - the basic methodology for conducting phone and will be tailored towards the those trials. I individual needs of each patient. It will 2 I Cancer Connection I Autumn 2 014 Control-Alt-Delete What’s the Frequency? Accordin gto the National Can - As electronic ce r Institute, more than a third of all human cancers, cigarettes (e-cigarettes) including a high percentage of pancreas, lung and become more popular, colon cancers, are driven by mutations in a family of research shows more de - that include better genes known as Ras. Ras has long been considered to fined survey measurements identification of be a target that does not respond to cancer treating are needed to better identify es - sustained e-ciga - drugs, but recent research suggests new possibilities. tablished users. The classification rette users are Activation of oncogenic Ras promotes tumor growth of ‘current use’ for instance, is con - needed. but also activates the cel lular self-cannibalization sidered as any use of the product in In related re- process of autophagy that recycles intracellular com - the past 30 days. “This definition in - search, Michael ponents to help sustain that growth. Eileen White, cludes those who experiment with the Steinberg, MD, MPH, FACP , direc - PhD (below) , associate director for basic science at device just one time and decide not to tor of the Tobacco Dependence Pro - Rutgers Cancer Institute of New Jersey, and col - do so again. They are being counted gram (supported by the Cancer Insti- leagues tested the consequence of removing the au - with those who may use e-cigarettes tute of New Jersey, School of Public tophagy gene ATG7 from laboratory models with several times a week or even daily,” Health and Rutgers Robert Wood non-small-cell says Cristine Delnevo, PhD, MPH , Johnson Medical School) and col - lung cancer.
Load more

Recommended publications
  • Internal Radiation Therapy, Places Radioactive Material Directly Inside Or Next to the Tumor
    Brachytherapy Brachytherapy is a type of radiation therapy used to treat cancer. It places radioactive sources inside the patient to kill cancer cells and shrink tumors. This allows your doctor to use a higher total dose of radiation to treat a smaller area in less time. Your doctor will tell you how to prepare and whether you will need medical imaging. Your doctor may use a computer program to plan your therapy. What is brachytherapy and how is it used? External beam radiation therapy (EBRT) directs high-energy x-ray beams at a tumor from outside the body. Brachytherapy, also called internal radiation therapy, places radioactive material directly inside or next to the tumor. It uses a higher total dose of radiation to treat a smaller area in less time than EBRT. Brachytherapy treats cancers throughout the body, including the: prostate - see the Prostate Cancer Treatment (https://www.radiologyinfo.org/en/info/pros_cancer) page cervix - see the Cervical Cancer Treatment (https://www.radiologyinfo.org/en/info/cervical-cancer-therapy) page head and neck - see the Head and Neck Cancer Treatment (https://www.radiologyinfo.org/en/info/hdneck) page skin breast - see the Breast Cancer Treatment (https://www.radiologyinfo.org/en/info/breast-cancer-therapy) page gallbladder uterus vagina lung - see the Lung Cancer Treatment (https://www.radiologyinfo.org/en/info/lung-cancer-therapy) page rectum eye Brachytherapy is seldom used in children. However, brachytherapy has the advantage of using a highly localized dose of radiation. This means that less radiation is delivered to surrounding tissue. This significantly decreases the risk of radiation-induced second malignancies, a serious concern in children.
    [Show full text]
  • Standards for Radiation Oncology
    Standards for Radiation Oncology Radiation Oncology is the independent field of medicine which deals with the therapeutic applications of radiant energy and its modifiers as well as the study and management of cancer and other diseases. The American College of Radiation Oncology (ACRO) is a nonprofit professional organization whose primary purposes are to advance the science of radiation oncology, improve service to patients, study the socioeconomic aspects of the practice of radiation oncology, and provide information to and encourage continuing education for radiation oncologists, medical physicists, and persons practicing in allied professional fields. As part of its mission, the American College of Radiation Oncology has developed a Practice Accreditation Program, consisting of standards for Radiation Oncology and standards for Physics/External Beam Therapy. Accreditation is a voluntary process in which professional peers identify standards indicative of a high quality practice in a given field, and which recognizes entities that meet these high professional standards. Each standard in ACRO’s Practice Accreditation Program requires extensive peer review and the approval of the ACRO Standards Committee as well as the ACRO Board of Chancellors. The standards recognize that the safe and effective use of ionizing radiation requires specific training, skills and techniques as described in this document. The ACRO will periodically define new standards for radiation oncology practice to help advance the science of radiation oncology and to improve the quality of service to patients throughout the United States. Existing standards will be reviewed for revision or renewal as appropriate on their third anniversary or sooner, if indicated. The ACRO standards are not rules, but rather attempts to define principles of practice that are indicative of high quality care in radiation oncology.
    [Show full text]
  • Section Ii: General Abstracting Instructions
    SECTION II: GENERAL ABSTRACTING INSTRUCTIONS 60 SECTION II: GENERAL ABSTRACTING INSTRUCTIONS It is the responsibility of every abstractor to know the content of the FCDS Data Acquisition Manual (DAM) and to update it upon receipt of any change from FCDS. Should you need training in cancer registry data collection, please visit the FCDS Learning Management System and consider taking the FCDS Abstracting Basics Course to gain a better understanding of the skills and training required to meet FCDS abstracting requirements and the national standards used when abstracting and coding cancer cases. This manual is intended to explain in detail each data item required for Florida Cancer Data System (FCDS) case reporting. It should be used as the primary information resource for any data item that must be coded and documented in accordance with Florida cancer reporting rules and statutes. Descriptions are only intended to provide sufficient detail to achieve consensus in submitting the required data. In no way does this manual imply any restriction on the type or degree of detail information collected, classified or studied within any healthcare facility-based cancer registry. Special Use Fields are available as needed. Basic Rules: 1) Always refer to the FCDS Data Acquisition Manual when completing an abstract. 2) Always submit a separate abstract for each reportable primary neoplasm identified. 3) Use leading zeros when necessary to right justify. 4) Text is required to adequately justify ALL coded values and to document supplemental information such as patient and family history of malignancy. Data items MUST be well documented in text field(s); specifically, Place of Diagnosis, Physical Exam, X-rays and Scans, Scopes and Diagnostic Tools, Surgical Procedures and Findings, Laboratory and Pathology (including: Dates of Specimen Collection, Primary Site, Histology, Behavior and Grade), and the Collaborative Stage data items including both core items and site specific factors.
    [Show full text]
  • Cancer Basics for the Caregiver It Is Common to Make Many Assumptions When You Hear the Word “Cancer.” Cancer Is Not One Disease, but Rather a Family of Diseases
    Caregiver’s Guide Types of Caregiving Caregiving can range from 24/7 hands-on assistance to driving someone to appointments to long-distance caregiving. Every situation is different. Your loved one has cancer and you want to help. At first, it all seems overwhelming. Everything that you took for granted is suddenly uncertain. Many caregivers are naturally worried about the person with cancer, and also worried about the rest of life—taking care of other family members, paying the bills, maintaining the house, and so much more. It’s important to realize two things: 1) You’re not alone— many other people have been in this situation before, and 2) there are resources available to help. We’ve prepared this booklet to guide and assist you. Much depends on the needs of the patient, your What’s essential is to understand that the role of the relationship with the patient, and practical matters loved one is to support and comfort, not to “fix” the such as where you live. problem. Every caregiving situation has the potential to be both When people are diagnosed with cancer, they don’t rewarding and stressful—often at the same time. want their loved ones to say, “I promise you that you’ll be cured.” In addition to worrying about your loved one’s cancer, you may be running the household, struggling What they want to hear is, “I love you and I’ll be here with piles of incomprehensible insurance forms, with you for whatever comes.” communicating with far-flung family members, and trying to earn enough money to pay the mounting bills.
    [Show full text]
  • The Impact of County-Level Radiation Oncologist Density on Prostate Cancer Mortality in the United States
    Prostate Cancer and Prostatic Diseases (2012) 15, 391 -- 396 & 2012 Macmillan Publishers Limited All rights reserved 1365-7852/12 www.nature.com/pcan ORIGINAL ARTICLE The impact of county-level radiation oncologist density on prostate cancer mortality in the United States S Aneja1 and JB Yu1,2,3 BACKGROUND: The distribution of radiation oncologists across the United States varies significantly among geographic regions. Accompanying these variations exist geographic variations in prostate cancer mortality. Prostate cancer outcomes have been linked to variations in urologist density, however, the impact of geographic variation in the radiation oncologist workforce and prostate cancer mortality has yet to be investigated. The goal of this study was to determine the effect of increasing radiation oncologist density on regional prostate cancer mortality. METHODS: Using county-level prostate cancer mortality data from the National Cancer Institute and Centers for Disease Control as well as physician workforce and health system data from the Area Resource File a regression model was built for prostate cancer mortality controlling for categorized radiation oncologist density, urologist density, county socioeconomic factors and pre-existing health system infrastructure. RESULTS: There was statistically significant reduction in prostate cancer mortality (3.91--5.45% reduction in mortality) in counties with at least 1 radiation oncologist compared with counties lacking radiation oncologists. However, increasing the density of radiation oncologists beyond 1 per 100 000 residents did not yield statistically significant incremental reductions in prostate cancer mortality. CONCLUSIONS: The presence of at least one radiation oncologist is associated with significant reductions in prostate cancer mortality within that county. However, the incremental benefit of increasing radiation oncologist density exhibits a plateau effect providing marginal benefit.
    [Show full text]
  • Welcome to the Cancer Resource Center!
    Welcome to the Cancer Resource Center! We understand that this is a difficult time for you and your family. We are here to offer assistance throughout your diagnosis, treatment, recovery, and beyond. The welcome folder describes some of the services and support we provide to individuals and families affected by cancer. Please don’t hesitate to contact us if you have questions about any information contained in this folder. Our staff is happy to talk with you one-on-one to answer questions and to provide information and resources available both locally and nationally. We meet with couples and families as well and we always respect the confidentiality of everyone we meet with. We share information only when given permission to do so. CRC has a lending library of books and other materials that covers a wide range of cancer-related topics as well as a boutique featuring free wigs, hats, scarves, and other items that can be useful during some types of treatment. Our many support groups for individuals with cancer and their loved ones play an important role in providing assistance and connection to others with similar experiences. Our Financial Advocacy program can help provide assistance with financial concerns if needed. Our website (www.crcfl.net) includes many additional resources that may be of assistance to you and your family. We encourage you to visit it. If you do not have a computer, we will be happy to assist you in finding cancer-related information that we can mail to you. Our staff and volunteers are here to help you in any way we can.
    [Show full text]
  • 1 2 3 4 5 6 7 8 9 10 11 12 13 1 Presidential Advisory Committee
    Presidential Advisory Committee 1 Department of Health and Human Services Centers for Disease Control and Prevention (CDC) National Institute for Occupational Safety and Health 1 (NIOSH) Advisory Board on Radiation and Worker Health 2 3 4 VOLUME I 5 6 7 The verbatim transcript of the Meeting of the Advisory Board on Radiation and Worker Health 8 held at the Washington Court Hotel, 525 New Jersey Avenue, N.W., Washington, D.C., on May 2 and 3, 9 2002. 10 NANCY LEE & ASSOCIATES Certified Verbatim Reporters P.O. Box 451196 11 Atlanta, Georgia 31145-9196 (404) 315-8305 12 13 C O N T E N T S 2 Vol. I Registration and Welcome Dr. Paul Ziemer, Chair 1 Mr. Larry Elliott, Executive Secretary. .8 Welcome and Opening Remarks Dr. Kathleen Rest, NIOSH . .11 2 Review and Approval of Draft Minutes Dr. Paul Ziemer, Chair. 18 3 Program Status Report Mr. Larry Elliott, Executive Secretary . .36 Changes to Probability of Causation Rule 4 (42 CFR Part 82) Mr. Ted Katz, NIOSH . 70 NCI-IREP 5 Dr. Charles Land, NCI . 82 NIOSH-IREP in use by DOL Dr. Mary Schubauer-Berigan, NIOSH . .115 6 Mr. Russ Henshaw, NIOSH . .176 Topics for Future Discussion Dr. Paul Ziemer, Chair . 193 7 Public Comment . 207 Discussion of Changes in the Rule . .216 8 Adjourn . .223 9 10 11 12 13 C O N T E N T S 3 Vol. II Registration and Welcome Dr. Paul Ziemer, Chair Mr. Larry Elliott, Executive Secretary . 227 1 Administrative Housekeeping Ms. Cori Homer, NIOSH . .227 2 Discussion of Rules.
    [Show full text]
  • Taking It Step by Step: a Guide for Women Diagnosed with Gynecological Cancer
    Taking it Step by Step A GUIDE FOR WOMEN DIAGNOSED WITH GYNECOLOGICAL CANCER With great thanks In This Guide Taking it Step by Step: A guide for women 1 Understanding Your Diagnosis _________ 3 diagnosed with gynecological cancer was envisioned and created by the BC/Yukon 2 Treatment Pathway & Timelines _______ 5 Women’s Cancer Information & Support Alliance. This group’s collaborative effort 3 Your Cancer Type _______________________6 includes: women with gynecological cancers; Uterine Cancer __________________________________6 the Canadian Cancer Society BC & Yukon; the Ovarian/Fallopian Tube Cancer ________________9 Gynecologic Tumour Group and Supportive Care Cervical Cancer ________________________________12 Professionals, BC Cancer Agency; Ovarian Cancer Vulvar Cancer __________________________________15 Canada Pacific Yukon Region and UBC School of Vaginal Cancer _________________________________17 Physical Therapy. The production and design for Taking it Step 4 Understanding Your Pathology Report _19 by Step was generously funded by the Cancer Program, Public Health Agency of Canada. The 5 Getting Ready _________________________20 views expressed herein do not represent the views of the Public Health Agency of Canada 6 Questions For Your Medical Team _____21 The printing and ongoing evaluation of Taking 7 Other Common Questions ____________22 it Step by Step is generously funded by the BC Cancer Foundation. The BC Cancer Foundation 8 Your Emotions __________________________23 is an independent charitable organization that raises
    [Show full text]
  • Integrative Oncology Program Focuses on Optimizing Cancer Treatment and a Return to Wellness
    VOLUME 8 • ISSUE 1 A NEWSLETTER FOR CANCER SURVIVORS Sponsored by the Dr. Diane Barton Complementary Medicine Program Integrative Oncology Program Focuses on Optimizing Cancer Treatment and a Return to Wellness “Hippocrates, the Greek physician and “father of medicine,” whose plements, physical activity and stress modifcation for patients who have com- oath all physicians take before entering into the practice of pleted cancer therapy. medicine, once said, “It is more important to know what sort of MD Anderson Cancer Center in Hous- person has a disease than to know what sort of disease a person ton, TX has been at the forefront of can- has.” This quote captures the essence of Integrative Medicine, a cer care for decades and was one of the feld that combines the best of mainstream, conventional therapies frst cancer centers in the nation to develop a program in integrative medicine. Fol- with complementary therapies while optimizing a healthy lifestyle, lowing their lead, and under Dr. Mehta’s all in a manner that is truly evidence-based.” – Pallav K. Mehta, MD guidance, the Integrative Oncology Pro- gram at MD Anderson Cooper focuses on he paradigm of cancer care approach, MD Anderson Coop- incorporating the three pillars of a healthy Thas been shifting greatly er has created the Integrative lifestyle – nutrition, physical activity and over the past decade and con- Oncology Program, led by emotional health – into the patient’s care tinues to do so at a rapid pace. Pallav K. Mehta, MD. plan, no matter where they are in their Advances in surgical tech- Dr. Mehta comes to MD An- cancer journey.
    [Show full text]
  • K Breast Diseases K Hyperplasia Hyperplasia Is an Overgrowth of Cells That Most Often Occurs on the Inside of the Lobules Or Milk Ducts in the Breast
    k Breast Diseases k Hyperplasia Hyperplasia is an overgrowth of cells that most often occurs on the inside of the lobules or milk ducts in the breast. There are two main types of hyperplasia—usual and atypical. Both increase the risk of breast cancer, though atypical hyperplasia does so to a greater degree. k Cysts Cysts are fluid-filled sacs that are almost always benign and more common in premenopausal women. After menopause, cysts occur less often. Cysts do not increase the risk of breast cancer. Although most cysts are too small to feel, some are large enough that they may feel like lumps in the breast and may cause breast pain. k Fibroadenomas Fibroadenomas are solid benign tumors most common in younger women, between the ages of 15 and 35. Most fibroadenomas do not increase the risk of breast cancer. Often, they do not need treatment. However, if a fibroadenoma is large or causes discomfort or worry, it may be removed. k Intraductal papillomas Intraductal papillomas are small growths that occur in the milk ducts of the breasts and can cause nipple discharge. A lump may be felt, may be painful and are removed with surgery with need no further treatment. They do not increase the risk of breast cancer unless they have abnormal cells or there is ductal carcinoma in situ (DCIS) in the nearby tissue. k Sclerosing adenosis Sclerosing adenosis are small breast lumps caused by enlarged lobules. A lump may be felt and may be painful. Sclerosing adenosis may be found on a mammogram. Because it has a distorted shape, it may be mistaken for breast cancer.
    [Show full text]
  • Palliative Nursing Across the Spectrum of Care
    P1: SFK/XXX P2: SFK BLBK147-Stevens February 12, 2009 6:59 Palliative Nursing Across the Spectrum of Care Edited by Elaine Stevens Susan Jackson Stuart Milligan A John Wiley & Sons, Ltd., Publication iii P1: SFK/XXX P2: SFK BLBK147-Stevens February 12, 2009 6:59 Palliative Nursing i P1: SFK/XXX P2: SFK BLBK147-Stevens February 12, 2009 6:59 ii P1: SFK/XXX P2: SFK BLBK147-Stevens February 12, 2009 6:59 Palliative Nursing Across the Spectrum of Care Edited by Elaine Stevens Susan Jackson Stuart Milligan A John Wiley & Sons, Ltd., Publication iii P1: SFK/XXX P2: SFK BLBK147-Stevens February 12, 2009 6:59 This edition first published 2009 C 2009 by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing programme has been merged with Wiley’s global Scientific, Technical, and Medical business to form Wiley-Blackwell. Registered office John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom Editorial offices 9600 Garsington Road, Oxford, OX4 2DQ, United Kingdom 2121 State Avenue, Ames, Iowa 50014-8300, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell. The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Current and Future Development in Lung Cancer Diagnosis
    International Journal of Molecular Sciences Review Current and Future Development in Lung Cancer Diagnosis Reem Nooreldeen and Horacio Bach * Division of Infectious Diseases, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6H 3Z6, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-875-4111 (ext. 62107) Abstract: Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression. Keywords: lung cancer; diagnosis; imaging; biomarkers; predictors; body fluids 1. Introduction Lung cancer is the most common cause of cancer-related deaths in North America Citation: Nooreldeen, R.; Bach, H. and other developed countries. According to the 2020 special report on lung cancer, this Current and Future Development in disease is the most commonly diagnosed cancer and the leading cause of cancer death in Lung Cancer Diagnosis.
    [Show full text]